BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

20 years of making ibuprofen faster

Faster processes: Ibuprofen DC 85 helps to decrease production time and to reduce costs. Designed specifically for direct compression into tablets, Ibuprofen DC 85 offers a number of benefits compared to conventional formulations. A common challenge when processing ibuprofen is the relatively low melting point: the API gradually starts to melt during processing and can stick to the machinery – meaning production must be stopped to clean the tablet punches. The active ingredient in Ibuprofen DC 85, in contrast, is coated with a layer of nanomaterial, which provides protection during manufacturing. The result is reliable fault-free tableting production with higher output rates. Furthermore, as expensive wet granulation and compaction processing steps are no longer necessary, our customers can lower production costs.

Speed of action: Ibuprofen Sodium & Racemic Ibuprofen Lysinate (RIBL) dissolve faster than conventional ibuprofen. This means they provide more rapid and effective pain relief during the first hour – so patients are back to full speed in no time.

BASF, the world leader in generic APIs, has been deploying the industry’s most eco-efficient ibuprofen manufacturing process for over 20 years.

BASF Pharma Ingredients and Services
http://www.pharma-ingredients.basf.com/ibuprofen/Home.aspx
pharma-ingredients@basf.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here